Saturday 17 October 2026
Export CYVNY’s income statement to Excel — free account
Ceryvyn Therapeutics Ltd. - Unsponsored ADR
CYVNY Healthcare Biotechnology
Ceryvyn Therapeutics Ltd. - Unsponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $25,000.00, down 80.0% from fiscal 2024.
0.02
0.00
0.00%
Follow CYVNY
| Jun '25 | Dec '24 | Jun '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.22 | 1.52 | 2.88 | 5.00 | |
Current Ratio |
0.22 | 1.57 | 2.94 | 5.10 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 152.78% | 106.22% | 108.60% | |
Debt/Equity |
0.00 | (1.32) | (2.65) | (3.85) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(158.66) | (72.58) | (161.05) | (69.36) | |
Working Capital |
(201.07) | 52.38 | 124.14 | 133.75 | |
Capital Expenditures |
(0.01) | (0.01) | (0.03) | 0.00 | |
Net Current Asset Value |
(201.07) | (170.35) | (76.41) | (47.08) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.08 | 8.57 | 9.19 | 4.60 | |
Average Payables |
13.81 | 19.35 | 24.78 | 20.01 | |
Average Assets |
77.72 | 149.89 | 124.42 | 137.86 | |
Average Common Equity |
(103.46) | (56.12) | (13.92) | 26.68 |
Columns are period end dates